In cardiomyocytes and the heart, pharmacologic enhancement of eIF2α phosphorylation is protective in myocardial infarction (54, 55), although in other reports, antagonizing eIF2α phosphorylation upon reperfusion appears to be beneficial (56, 57). This evidence concerns the gene EIF2A and myocardial infarction.